Selected research
Industry Research
Nimodipine Sustained Release Tablets Industry Research Report 2026
Market perspective
The global Nimodipine Sustained Release Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Nimodipine Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Nimodipine Sustained Release Tablets is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Nimodipine Sustained Release Tablets is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Nimodipine Sustained Release Tablets include Arbor Pharmaceuticals, Bayer Vital, Bionpharma, Heritage Pharmaceuticals, Pharmaceutics International, Sofgen Pharmaceuticals, Wuhan HITECK Biopharmaceutical, Sihuan Pharmaceutical and Jiangsu Kanion Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Nimodipine Sustained Release Tablets market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nimodipine Sustained Release Tablets Market by Company
Arbor Pharmaceuticals
Bayer Vital
Bionpharma
Heritage Pharmaceuticals
Pharmaceutics International
Sofgen Pharmaceuticals
Wuhan HITECK Biopharmaceutical
Sihuan Pharmaceutical
Jiangsu Kanion Pharmaceutical
Qilu Pharmaceutical
Shandong Yunmen Pharmaceutical
Yabao Pharmaceutical Group
Nimodipine Sustained Release Tablets Segment by Type
30mg/Piece
60mg/Piece
Others
Nimodipine Sustained Release Tablets Segment by Application
Hospital
Pharmacy
Others
Nimodipine Sustained Release Tablets Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nimodipine Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nimodipine Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nimodipine Sustained Release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nimodipine Sustained Release Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nimodipine Sustained Release Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nimodipine Sustained Release Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 30mg/Piece
- 60mg/Piece
- Others
Applications
- Hospital
- Pharmacy
- Others
Companies covered
- Arbor Pharmaceuticals
- Bayer Vital
- Bionpharma
- Heritage Pharmaceuticals
- Pharmaceutics International
- Sofgen Pharmaceuticals
- Wuhan HITECK Biopharmaceutical
- Sihuan Pharmaceutical
- Jiangsu Kanion Pharmaceutical
- Qilu Pharmaceutical
- Shandong Yunmen Pharmaceutical
- Yabao Pharmaceutical Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Nimodipine Sustained Release Tablets Market Size (2021-2032)
- 2.2.2 Global Nimodipine Sustained Release Tablets Sales (2021-2032)
- 2.2.3 Global Nimodipine Sustained Release Tablets Market Average Price (2021-2032)
- 2.3 Nimodipine Sustained Release Tablets by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 30mg/Piece
- 2.3.3 60mg/Piece
- 2.3.4 Others
- 2.4 Nimodipine Sustained Release Tablets by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Nimodipine Sustained Release Tablets Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Nimodipine Sustained Release Tablets Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Nimodipine Sustained Release Tablets Revenue of Manufacturers (2021-2026)
- 3.4 Global Nimodipine Sustained Release Tablets Average Price by Manufacturers (2021-2026)
- 3.5 Global Nimodipine Sustained Release Tablets Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Nimodipine Sustained Release Tablets, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Nimodipine Sustained Release Tablets, Product Type & Application
- 3.8 Global Manufacturers of Nimodipine Sustained Release Tablets, Established Date
- 3.9 Global Nimodipine Sustained Release Tablets Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Arbor Pharmaceuticals
- 4.1.1 Arbor Pharmaceuticals Company Information
- 4.1.2 Arbor Pharmaceuticals Business Overview
- 4.1.3 Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
- 4.1.5 Arbor Pharmaceuticals Recent Developments
- 4.2 Bayer Vital
- 4.2.1 Bayer Vital Company Information
- 4.2.2 Bayer Vital Business Overview
- 4.2.3 Bayer Vital Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer Vital Nimodipine Sustained Release Tablets Product Portfolio
- 4.2.5 Bayer Vital Recent Developments
- 4.3 Bionpharma
- 4.3.1 Bionpharma Company Information
- 4.3.2 Bionpharma Business Overview
- 4.3.3 Bionpharma Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bionpharma Nimodipine Sustained Release Tablets Product Portfolio
- 4.3.5 Bionpharma Recent Developments
- 4.4 Heritage Pharmaceuticals
- 4.4.1 Heritage Pharmaceuticals Company Information
- 4.4.2 Heritage Pharmaceuticals Business Overview
- 4.4.3 Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
- 4.4.5 Heritage Pharmaceuticals Recent Developments
- 4.5 Pharmaceutics International
- 4.5.1 Pharmaceutics International Company Information
- 4.5.2 Pharmaceutics International Business Overview
- 4.5.3 Pharmaceutics International Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pharmaceutics International Nimodipine Sustained Release Tablets Product Portfolio
- 4.5.5 Pharmaceutics International Recent Developments
- 4.6 Sofgen Pharmaceuticals
- 4.6.1 Sofgen Pharmaceuticals Company Information
- 4.6.2 Sofgen Pharmaceuticals Business Overview
- 4.6.3 Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
- 4.6.5 Sofgen Pharmaceuticals Recent Developments
- 4.7 Wuhan HITECK Biopharmaceutical
- 4.7.1 Wuhan HITECK Biopharmaceutical Company Information
- 4.7.2 Wuhan HITECK Biopharmaceutical Business Overview
- 4.7.3 Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
- 4.7.5 Wuhan HITECK Biopharmaceutical Recent Developments
- 4.8 Sihuan Pharmaceutical
- 4.8.1 Sihuan Pharmaceutical Company Information
- 4.8.2 Sihuan Pharmaceutical Business Overview
- 4.8.3 Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
- 4.8.5 Sihuan Pharmaceutical Recent Developments
- 4.9 Jiangsu Kanion Pharmaceutical
- 4.9.1 Jiangsu Kanion Pharmaceutical Company Information
- 4.9.2 Jiangsu Kanion Pharmaceutical Business Overview
- 4.9.3 Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
- 4.9.5 Jiangsu Kanion Pharmaceutical Recent Developments
- 4.10 Qilu Pharmaceutical
- 4.10.1 Qilu Pharmaceutical Company Information
- 4.10.2 Qilu Pharmaceutical Business Overview
- 4.10.3 Qilu Pharmaceutical Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Qilu Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
- 4.10.5 Qilu Pharmaceutical Recent Developments
- 4.11 Shandong Yunmen Pharmaceutical
- 4.11.1 Shandong Yunmen Pharmaceutical Company Information
- 4.11.2 Shandong Yunmen Pharmaceutical Business Overview
- 4.11.3 Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
- 4.11.5 Shandong Yunmen Pharmaceutical Recent Developments
- 4.12 Yabao Pharmaceutical Group
- 4.12.1 Yabao Pharmaceutical Group Company Information
- 4.12.2 Yabao Pharmaceutical Group Business Overview
- 4.12.3 Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Product Portfolio
- 4.12.5 Yabao Pharmaceutical Group Recent Developments
5 Global Nimodipine Sustained Release Tablets Market Scenario by Region
- 5.1 Global Nimodipine Sustained Release Tablets Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Nimodipine Sustained Release Tablets Sales by Region: 2021-2032
- 5.2.1 Global Nimodipine Sustained Release Tablets Sales by Region: 2021-2026
- 5.2.2 Global Nimodipine Sustained Release Tablets Sales by Region: 2027-2032
- 5.3 Global Nimodipine Sustained Release Tablets Revenue by Region: 2021-2032
- 5.3.1 Global Nimodipine Sustained Release Tablets Revenue by Region: 2021-2026
- 5.3.2 Global Nimodipine Sustained Release Tablets Revenue by Region: 2027-2032
- 5.4 North America Nimodipine Sustained Release Tablets Market Facts & Figures by Country
- 5.4.1 North America Nimodipine Sustained Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
- 5.4.3 North America Nimodipine Sustained Release Tablets Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Nimodipine Sustained Release Tablets Market Facts & Figures by Country
- 5.5.1 Europe Nimodipine Sustained Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
- 5.5.3 Europe Nimodipine Sustained Release Tablets Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Nimodipine Sustained Release Tablets Market Facts & Figures by Country
- 5.6.1 Asia Pacific Nimodipine Sustained Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Nimodipine Sustained Release Tablets Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Nimodipine Sustained Release Tablets Market Facts & Figures by Country
- 5.7.1 South America Nimodipine Sustained Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
- 5.7.3 South America Nimodipine Sustained Release Tablets Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Nimodipine Sustained Release Tablets Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Nimodipine Sustained Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Nimodipine Sustained Release Tablets Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Nimodipine Sustained Release Tablets Sales by Type (2021-2032)
- 6.1.1 Global Nimodipine Sustained Release Tablets Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Nimodipine Sustained Release Tablets Sales Market Share by Type (2021-2032)
- 6.2 Global Nimodipine Sustained Release Tablets Revenue by Type (2021-2032)
- 6.2.1 Global Nimodipine Sustained Release Tablets Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Nimodipine Sustained Release Tablets Revenue Market Share by Type (2021-2032)
- 6.3 Global Nimodipine Sustained Release Tablets Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Nimodipine Sustained Release Tablets Sales by Application (2021-2032)
- 7.1.1 Global Nimodipine Sustained Release Tablets Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Nimodipine Sustained Release Tablets Sales Market Share by Application (2021-2032)
- 7.2 Global Nimodipine Sustained Release Tablets Revenue by Application (2021-2032)
- 7.2.1 Global Nimodipine Sustained Release Tablets Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Nimodipine Sustained Release Tablets Revenue Market Share by Application (2021-2032)
- 7.3 Global Nimodipine Sustained Release Tablets Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Nimodipine Sustained Release Tablets Value Chain Analysis
- 8.1.1 Nimodipine Sustained Release Tablets Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Nimodipine Sustained Release Tablets Production Mode & Process
- 8.2 Nimodipine Sustained Release Tablets Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Nimodipine Sustained Release Tablets Distributors
- 8.2.3 Nimodipine Sustained Release Tablets Customers
9 Global Nimodipine Sustained Release Tablets Analyzing Market Dynamics
- 9.1 Nimodipine Sustained Release Tablets Industry Trends
- 9.2 Nimodipine Sustained Release Tablets Industry Drivers
- 9.3 Nimodipine Sustained Release Tablets Industry Opportunities and Challenges
- 9.4 Nimodipine Sustained Release Tablets Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst